Graybill Bartz Assoc Ltd Exits Position in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Graybill Bartz Assoc Ltd has sold out all of its stake in Eli Lilly and Co during the most recent quarter, according to a report filed by the company on Apr 5, 2016 with the SEC. The investment management company has sold out 2,606 shares of Eli Lilly and Co which is valued at $192,714.

Other Hedge Funds, Including , Lvm Capital Management Ltdmi reduced its stake in LLY by selling 3,500 shares or 6.62% in the most recent quarter. The Hedge Fund company now holds 49,332 shares of LLY which is valued at $3.6 Million. Eli Lilly and Co makes up approx 1.16% of Lvm Capital Management Ltdmi’s portfolio.

On the company’s financial health, Eli Lilly and Co reported $0.78 EPS for the quarter, based on the information available during the earnings call on Jan 28, 2016. Analyst had a consensus estimate of $0.78. The company had revenue of $5375.60 million for the quarter, compared to analysts expectations of $5327.26 million. The company’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.75 EPS.

Many Wall Street Analysts have commented on Eli Lilly and Co. Societe Generale Initiated Eli Lilly and Co on Apr 6, 2016 to “Hold”, Price Target of the shares are set at $78.

Eli Lilly and Co closed down -0.44 points or -0.59% at $73.95 with 33,51,100 shares getting traded on Monday. Post opening the session at $74.48, the shares hit an intraday low of $73.795 and an intraday high of $74.74 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.